RPL9P2

Across TCGA pan-cancer cohorts, RPL9P2 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RPL9P2’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where RPL9P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL9P2 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

CHOL, BRCA, and KIRP are the cancer types where RPL9P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL9P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	II,III,IV	+0.605	<.001	4	view →
BRCA	All	III,IV	−0.283	.010	2	view →
KIRP	All	IV	+0.232	.038	2	view →
KIRC	All	All	+0.097	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RPL9P2–CHOL

Open the CHOL breakdown →